1 September 2015 in Clinical Gastroenterology and Hepatology
Patients with serrated polyposis develop multiple colorectal hyperplastic and/or serrated sessile adenomas/polyps. We investigated the risk of colorectal and other cancers by analyzing data from 64 patients with serrated polyposis (mean age at diagnosis, 54 y; 41% men; 92% white) listed in the Johns Hopkins Polyposis Registry. Medical, endoscopic, and histopathology reports were evaluated. Six patients (9.4%) had a history of colorectal cancer, diagnosed at a mean age of 56 years; 6 additional patients (9.4%) had at least 1 advanced colorectal adenoma. Extracolonic cancers were found in 16% of the study population. The standard incidence ratio for colorectal cancer in patients with serrated polyposis was 18.72 (95% confidence interval, 6.87-40.74) and for extracolonic cancer was 31.20 (95% confidence interval, 14.96-57.37), compared with the Surveillance, Epidemiology, and End Results population. Patients with serrated polyposis therefore have a high risk for colorectal cancer and require vigilant colorectal surveillance, starting at the time of diagnosis of serrated polyposis. The risk of extracolonic cancer also appears to be increased, but this requires further evaluation.
15 November 2007 in Expert Opinion on Pharmacotherapy
1 January 2025 in Case Reports in Oncology
JIJesus Izaguirre-Carbonell
Jesus Izaguirre-Carbonell
Introduction: Tumor-informed minimal residual disease (MRD) monitoring assays based on plasma circulating tumor DNA (ctDNA) are increasingly integrated into the clinical management of patients with cancer. In the post-surgical curative intent setting and as an adjunct to radiographic imaging for response assessment and surveillance, timely identification of MRD may better guide therapeutic decision-making. The increasing clinical adoption of MRD testing, supported by a growing body of evidence demonstrating its potential utility at critical decision points across diverse tumor histology, has brought attention to the variability in the analytical performance of available ctDNA assays. This variability is becoming increasingly appreciated as a key factor influencing clinical performance. Case Presentations: Here we report a case series in breast and rectal cancer involving treatment monitoring with a novel advanced MRD assay, illustrating its ability to identify subclinical metastasis and disease resolution below the validated limit of detection of a commercially available ctDNA assay in these cases. Conclusion: Results aided medical decision-making and underscored the need for highly sensitive assays in MRD detection. The differences in sensitivity, driven primarily by analytical variables, highlight the importance of selecting an assay that is not only analytically robust but also appropriately matched to the patient’s specific clinical context, to help ensure optimal utility and minimize the risk of misinterpretation.
20 August 2026 in The Journal of Molecular Diagnostics